Year 2020 / Volume 112 / Number 2
Review
Metabolic syndrome, non-alcoholic fatty liver disease and hepatocarcinoma

133-138

DOI: 10.17235/reed.2020.6640/2019

Mario Serradilla Martín, José Ramón Oliver Guillén, Ana Palomares Cano, José Manuel Ramia Ángel,

Abstract
The term “metabolic syndrome” refers to a group of alterations comprising central obesity reduced high-density lipoprotein cholesterol concentrations, elevated triglyceride concentrations, arterial hypertension, and hyperglycemia. This syndrome has established itself as one of the epidemics of the 21st century. Among its causative agents are insulin resistance, leptin and adiponectin, changes in microbiota, and epigenetics. Its incidence in the European population is estimated to be around 25%. Non-alcoholic fatty liver disease is the hepatic manifestation of metabolic syndrome; its prevalence parallels that of obesity, and it has increased exponentially in recent decades. Recently, several publications have linked metabolic risk factors with the onset and development of hepatocarcinoma, and so it is essential to determine whether patients with non-alcoholic fatty liver disease should follow a protocol for hepatocarcinoma screening. At present, the worldwide incidence of hepatocarcinoma in patients with non-alcoholic fatty liver disease without cirrhosis is only 2.7%. Screening for hepatocarcinoma in patients with non-alcoholic fatty liver disease and cirrhosis is mandatory, but the low incidence of hepatocarcinoma in patients without cirrhosis does not justify the systematic monitoring of this patient population. Current efforts are based on identifying subgroups of patients with non-alcoholic fatty liver disease and a higher-than-average risk of developing hepatocarcinoma.
Share Button
New comment
Comments
No comments for this article
References
1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365(9468):1415-28.
2. Zimmet PZ, Alberti KGMM, Shaw JE. Mainstreaming the metabolic syndrome: a definitive definition. Med J Aust 2005;183(4):175-6.
3. Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis 2017;14:E24.
4. Jinjuvadia R, Patel S, Liangpunsakul S. The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol 2014;48(2):172-7.
5. Gluvic Z, Zaric B, Resanovic I, et al. Link between Metabolic Syndrome and Insulin Resistance. Curr Vasc Pharmacol 2017;15(1):30-9.
6. Caligiuri A, Gentilini A, Marra F. Molecular pathogenesis of NASH. Int J Mol Sci 2016;17(9):E1575.
7. Nistal E, Sáenz de Miera LE, Ballesteros Pomar M, et al. An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity. Rev Esp Enferm Dig 2019;111(4):275-82.
8. Albillos A, Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol 2019;14:S0168-8278(19)30604-X. [Epub ahead of print]
9. Bashiardes S, Shapiro H, Rozin S, et al. Non-alcoholic fatty liver and the gut microbiota. Mol Metab 2016;5(9):782-94.
10. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328-57.
11. Kim D, Kim WR, Kim HJ, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57(4):1357-65.
12. Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2016;17(5):E774.
13. Albhaisi S, Sanyal A. Recent advances in understanding and managing non-alcoholic fatty liver disease. F1000Res 2018;7:F1000 Faculty Rev-720.
14. Younes R, Bugianesi E. NASH in Lean Individuals. Semin Liver Dis 2019;39(1):86-95.
15. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(06):1388-402.
16. Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017;71:17-32.
17. Angelico F, Burattin M, Alessandri C, et al. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Angelico F, ed. Cochrane database Syst Rev 2007;(1):CD005166.
18. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-14.
19. Li Y, Shi J, Liu X et al. Metabolic syndrome relates to high risk in hepatocellular carcinoma: a meta-analysis. Discov Med 2018;26(144):185-96.
20. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012;10:1342-59.
21. Reig M, Gambato M, Man NK, et al. Should Patients With NAFLD/NASH Be Surveyed for HCC? Transplantation 2019;103(1):39-44.
22. Lee TY, Wu JC, Yu SH, et al. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer 2017;141:1307-14.
23. Kim GA, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol 2018;68:140-6.
24. EASL; EASD; EASO. EASL-EASD-EASO clinical practice guidelines for the Management of non-Alcoholic Fatty Liver Disease. Obes Facts 2016;9:65-90.
25. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonal- coholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
Related articles

Review

Immunotherapy in hepatocellular carcinoma

DOI: 10.17235/reed.2022.8876/2022

Letter

Biopsy for hepatocellular carcinoma: only occasionally

DOI: 10.17235/reed.2020.6935/2020

Letter

Hepatocarcinoma diagnosis. Reflection is required

DOI: 10.17235/reed.2020.6845/2019

Letter

Rhabdomyolysis in a patient under treatment with sorafenib

DOI: 10.17235/reed.2020.6440/2019

Case Report

Ectopic hepatocellular carcinoma arising from the peritoneum

DOI: 10.17235/reed.2019.6408/2019

Original

Colonic diverticulosis and the metabolic syndrome: an association?

DOI: 10.17235/reed.2017.5009/2017

Digestive Diseases Image

Debut of an unusual liver cirrhosis

Citation tools
Serradilla Martín M, Oliver Guillén J, Palomares Cano A, Ramia Ángel J. Metabolic syndrome, non-alcoholic fatty liver disease and hepatocarcinoma. 6640/2019


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1347 visits.
This article has been downloaded 573 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 21/09/2019

Accepted: 03/01/2020

Online First: 05/02/2020

Published: 07/02/2020

Article revision time: 99 days

Article Online First time: 137 days

Article editing time: 139 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology